FDA Approves Implant for Nearsightedness

Article

The FDA approved a corneal implant to correct near-sightedness.

The US Food and Drug Administration (FDA) today approved a device implanted in the cornea of one eye for some patients with presbyopia. It will not work if patients do not have clear distance vision.

It is the second FDA-approved implantable corneal device for correction of near-sightedness. It is meant only for patients who have not had cataract surgery, the FDA noted.

The devices is marketed as the Raindrop Near Vision Inlay. It is made by Revision Optics, Inc. of Lake Forest, CA.

The device is not for patients with severe dry eye, active eye infection, corneal disease characterized by general thinning and cone-shaped protrusion in the center of the cornea, and certain other conditions including uncontrolled diabetes.

The implant proved safe and effective in a clinical trial of 373 patients of whom 92% were able to see with 20/40 vision or better at near distances with the inlay.

According to the FDA, the implant could be an alternative to reading glasses or bifocals.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.